These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32270727)

  • 61. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
    Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
    Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
    Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
    J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma].
    Feng J; Wu J; Song Y; Su L; Zhang M; Li W; Hu Y; Zhang X; Gao Y; Niu Z; Feng R; Wang W; Peng J; Ouyang X; Li X; Wu C; Zhang W; Zeng Y; Xiao Z; Liang Y; Zhuang Y; Wang J; Sun Z; Bai H; Cui T
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):309-13. PubMed ID: 24759018
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Economic Burden of Veno-occlusive Disease in Patients With B-cell Acute Lymphoblastic Leukemia in the United States.
    Zhang X; Song X; Lopez-Gonzalez L; Jariwala-Parikh K; Romanov V; Cong Z
    Clin Ther; 2018 Oct; 40(10):1711-1719.e1. PubMed ID: 30196935
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.
    Merchionne F; Quintana G; Gaudio F; Minoia C; Specchia G; Guarini A; Quarta G; Pavone V; Melpignano A
    Leuk Res; 2014 Dec; 38(12):1446-50. PubMed ID: 25455656
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
    Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K
    Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer.
    Aly A; Shah R; Hill K; Botteman MF
    Future Oncol; 2019 Mar; 15(9):1007-1020. PubMed ID: 30717602
    [TBL] [Abstract][Full Text] [Related]  

  • 70. How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
    Gisselbrecht C; Van Den Neste E
    Br J Haematol; 2018 Sep; 182(5):633-643. PubMed ID: 29808921
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Economic burden of treatment failure in chronic lymphocytic leukemia patients.
    Wang S; Lafeuille MH; Lefebvre P; Romdhani H; Emond B; Senbetta M
    Curr Med Res Opin; 2018 Jun; 34(6):1135-1142. PubMed ID: 29649904
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
    Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
    Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
    Gyan E; Damotte D; Courby S; Sénécal D; Quittet P; Schmidt-Tanguy A; Banos A; Le Gouill S; Lamy T; Fontan J; Maisonneuve H; Alexis M; Dreyfus F; Tournilhac O; Laribi K; Solal-Céligny P; Arakelyan N; Cartron G; Gressin R;
    Br J Haematol; 2013 Jul; 162(2):240-9. PubMed ID: 23692641
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study.
    Jakobsen LH; Bøgsted M; Brown PN; Arboe B; Jørgensen J; Larsen TS; Juul MB; Schurmann L; Højberg L; Bergmann OJ; Lassen T; Josefsson PL; Jensen P; Johnsen HE; El-Galaly TC
    J Clin Oncol; 2017 Mar; 35(7):778-784. PubMed ID: 28095160
    [TBL] [Abstract][Full Text] [Related]  

  • 77. T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
    Tsirigotis P; Economopoulos T; Rontogianni D; Dervenoulas J; Papageorgiou E; Bollas G; Mantzios G; Kalantzis D; Koumarianou A; Raptis S
    Oncology; 2001; 61(4):257-64. PubMed ID: 11721171
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
    Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
    Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
    Hamlin PA; Zelenetz AD; Kewalramani T; Qin J; Satagopan JM; Verbel D; Noy A; Portlock CS; Straus DJ; Yahalom J; Nimer SD; Moskowitz CH
    Blood; 2003 Sep; 102(6):1989-96. PubMed ID: 12676776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.